Outcome of Board Meeting

FY2026 results (audited): Standalone: Revenue 886.6bn (Rs in lakhs 88660.95) (no prior year for y-y) PAT 72.9bn (Rs in lakhs 7287.02) (no prior year for y-y) Q2FY27 results (unaudited): Standalone: Revenue 27.42bn +30.7% y-y (20.98bn) EBITDA 5.13bn +29.8% y-y (3.95bn) EBITDA margin 18.7% (18.8%) -10 bps y-y PAT 2.11bn +36.1% y-y (1.55bn) H1FY27 results (unaudited): Standalone: Revenue 57.47bn +27.6% y-y (45.03bn) EBITDA 10.77bn +24.0% y-y (8.68bn) EBITDA margin 18.7% (19.3%) -60 bps y-y PAT 4.67bn +23.2% y-y (3.79bn) Dividend: Rs 3/share final dividend recommended for FY2026 (face value Rs 5), total dividend 100% (Rs 5/share) including interim dividend Commentary: Despite geopolitical challenges and raw material price increases, the company successfully passed on costs, improved operational efficiencies, and achieved strong volume and profit growth, with Pharma and Food & FMCG packaging as key growth drivers.